Pharmafile Logo
Pharmafocus logo
Advanced Search

ipilimumab

Showing 7 posts of 7 posts found.

Opdivo

EMA approves BMS’ Opdivo for advanced skin cancer

April 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer

Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …

News
Keytruda image

Merck’s Keytruda trial stopped early after beating BMS’ Yervoy on survival

March 25, 2015
Research and Development, Sales and Marketing BMS, Merck, Yervoy, ipilimumab, keytruda, pembrolizumab

A trial comparing two potential blockbuster cancer treatments has been stopped early, after Merck’s Keytruda beat BMS’ Yervoy in a …

News
Yervoy (ipilimumab)

BMS launches skin cancer treatment Yervoy in UK

August 22, 2011
Sales and Marketing Yervoy, cancer vaccine, ipilimumab, skin cancer

Bristol-Myers Squibb’s skin cancer treatment Yervoy has been launched in the UK for patients with the deadliest form of the …

News

European approval for BMS skin cancer vaccine

July 14, 2011
Sales and Marketing BMS, Yervoy, ipilimumab

Bristol-Myers Squibb’s skin cancer vaccine Yervoy has been approved in Europe after showing survival benefits in one of the most …

News

BMS skin cancer vaccine hits phase III target

March 23, 2011
Research and Development BMS, Bristol-Myers Squibb, advanced inoperable skin cancer, advanced melanoma, cancer drugs, cancer vaccine, ipilimumab

Bristol Myers Squibb’s cancer vaccine ipilimumab has increased overall survival in advanced melanoma patients. The therapy was being tested as …

News
Advanced melanoma

BMS skin cancer drug hits US regulatory delay

November 3, 2010
Research and Development BMS, Bristol-Myers Squibb, FDA, MDX010-020 trial, ipilimumab, skin cancer

US regulators have announced they need more time to assess Bristol-Myers Squibb’s skin cancer treatment ipilimumab. The FDA will not …

News
melanoma

BMS’ melanoma drug given priority review

August 19, 2010
Sales and Marketing BMS, ipilimumab

Bristol-Myers Squibb’s promising new treatment for skin cancer melanoma has been given a priority review by the FDA. The company …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024